Samo Guzelj (Author), Matjaž Weiss (Author), Bram Slütter (Author), Ruža Frkanec (Author), Žiga Jakopin (Author)

Abstract

The success of vaccination with subunit vaccines often relies on the careful choice of adjuvants. There is great interest in developing new adjuvants that can elicit a cellular immune response. Here, we address this challenge by taking advantage of the synergistic cross-talk between two pattern recognition receptors: nucleotide-binding oligomerization-domain-containing protein 2 (NOD2) and Toll-like receptor 7 (TLR7). We designed two conjugated NOD2/TLR7 agonists, which showed potent immunostimulatory activities in human primary peripheral blood mononuclear cells and murine bone-marrow-derived dendritic cells. One of these, 4, also generated a strong antigen-specific immune response in vivo, with a Th1-polarized profile. Importantly, our study shows that novel NOD2/TLR7 agonists elicit sophisticated and fine-tuned immune responses that are inaccessible to individual NOD2 and TLR7 agonists.

Keywords

immunostimulatory activity;vaccines;immune responses;pattern recognition receptors;synthesis of NOD2 agonist;Toll-like receptor 7;

Data

Language: English
Year of publishing:
Typology: 1.01 - Original Scientific Article
Organization: UL FFA - Faculty of Pharmacy
UDC: 615.371:616-097
COBISS: 128189187 Link will open in a new window
ISSN: 1520-4804
Views: 80
Downloads: 65
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary language: Slovenian
Secondary keywords: imunostimulatorna aktivnost;imunski odziv;receptorji za prepoznavanje vzorcev;sinteza agonista NOD2;Tollu podoben receptor 7;Cepiva;Imunski odziv;
Type (COBISS): Article
Pages: str. 15085–15101
Volume: ǂVol. ǂ65
Issue: ǂno. ǂ22
Chronology: 2022
DOI: 10.1021/acs.jmedchem.2c00808
ID: 17361110